The diversified firm, BPH Energy Limited (ASX:BPH) has released its preliminary final report for the financial year ended June 2020 on the ASX. BPH has noted a net profit after tax of $1.37 million for the period, as against a loss of $3.01 million in FY 2019.
The key activities undertaken by the Company and its investee players during the year include:
BPH Energy
- Completion of 1 for 10 share consolidation.
- Agreement to acquire an initial investment of 10% in Patagonia Genetics Pty Ltd (PG Aust).
Patagonia Genetics Pty Ltd
- Purchase of first 1,300ltrs of Wonderland Agronutrients products.
Cortical Dynamics Limited
- Trial of Brain Anaesthesia Response Monitor (BARM) at Southampton University Hospital in the UK.
- Receipt of Korean KGMP certification by Globaluck, which is Cortical’s South Korean exclusive distributor of the BARM.
- Investment secured from IntuitiveX and Gentium Partners.
- Signing of a non-exclusive Licence and Co-operation Agreement with Philips.
- Commencement of the FDA 510K filing process for BARM in the US.
Advent Energy Limited
- Termination of the RL Energy Joint Venture Agreement for the PEP11 permit by mutual consent.
- Submission of application to National Offshore Petroleum Titles Administrator (NOPTA) for drilling at PEP 11 permit.
- Renewal of Retention Licence 1 in Northern Territory.
BPH is trading at $0.032 mid-day on 1 September 2020.